期刊文献+

复方丹参注射液联合伊马替尼治疗急性淋巴细胞白血病临床研究

Clinical Study on Compound Danshen Injection Combined with Imatinib for Acute Lymphoblastic Leukemia
下载PDF
导出
摘要 目的:观察复方丹参注射液联合伊马替尼对急性淋巴细胞白血病患者造血及免疫功能的影响。方法:选择70例急性淋巴细胞白血病患者为研究对象,按随机数字表法分为对照组和观察组各35例。对照组给予化疗+伊马替尼治疗,观察组在对照组基础上给予复方丹参注射液治疗。比较2组临床疗效,检测治疗前后血白细胞(WBC)、红细胞(RBC)、血小板(BPC)计数和血红蛋白(Hb)水平的变化,检测外周血T淋巴细胞亚群(CD3^(+),CD4^(+),CD8^(+)及CD4^(+)/CD8^(+))水平的变化。结果:治疗前,2组外周血WBC、RBC、BPC计数及Hb水平比较,差异无统计学意义(P>0.05)。治疗后,2组外周血RBC、BPC计数及Hb水平较治疗前上升,WBC计数较治疗前下降(P<0.05);且观察组WBC、RBC及Hb高于对照组(P<0.05)。治疗前,2组CD3^(+)、CD4^(+)、CD8^(+)及CD4^(+)/CD8^(+)水平比较,差异无统计学意义(P>0.05)。治疗后,2组CD3^(+)、CD4^(+)及CD4^(+)/CD8^(+)水平较治疗前降低(P<0.05),但是观察组降低程度小于对照组(P<0.05)。结论:复方丹参注射液联合伊马替尼治疗急性淋巴细胞白血病具有较好的疗效,可以有效改善患者骨髓造血功能和免疫功能。 Objective:To observe the effect of compound Danshen injection combined with imatinib on hematopoiesis and immune function of patients with acute lymphoblastic leukemia.Methods:A total of 70 cases of patients with acute lymphoblastic leukemia were selected as study objects,and were divided into the control group and the observation group according to the random number table method,with 35 cases in each group.The control group was treated with chemotherapy and imatinib,and the observation group was additionally treated with compound Danshen injection based on the treatment of the control group.The clinical effects in the two groups were compared;the changes in the levels of white blood cell(WBC),red blood cell(RBC),blood platelet count(BPC)and hemoglobin(Hb)before and after treatment were detected;the changes in the levels of T lymphocyte subsets including CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)in peripheral blood were detected.Results:Before treatment,there was no significant difference being found in the comparison of the counts of WBC,RBC,BPC and the Hb levels between the two groups(P>0.05).After treatment,the counts of RBC and BPC and the Hb levels in peripheral blood in the two groups were increased when compared with those before treatment,and WBC counts were decreased(P<0.05);WBC,RBC and Hb in the observation group were higher than those in the control group(P<0.05).Before treatment,there was no significant difference being found in the comparison of the levels of CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)between the two groups(P>0.05).After treatment,the levels of CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)in the two groups were decreased when compared with those before treatment(P<0.05),but the decrease in the observation group was less significant than that in the control group(P<0.05).Conclusion:The therapy of compound Danshen injection combined with imatinib has a good curative in the treatment of acute lymphoblastic leukemia,which can effectively improve bone marrow hematopoietic function and immune function of patients.
作者 冯沈红 郑仁智 赵建治 FENG Shenhong;ZHENG Renzhi;ZHAO Jianzhi
出处 《新中医》 CAS 2022年第19期182-185,共4页 New Chinese Medicine
关键词 急性淋巴细胞白血病 复方丹参注射液 伊马替尼 骨髓抑制 免疫功能 血常规 Acute lymphoblastic leukemia Compound Danshen injection Imatinib Myelosuppression Immune function Blood routine
  • 相关文献

参考文献13

二级参考文献71

  • 1陆英,钟雪云,陈运贤,陈求刚,陈志勇,林东军.参芪扶正注射液对化疗后小鼠造血功能影响的实验研究[J].热带医学杂志,2005,5(6):750-752. 被引量:24
  • 2Chen W, Luo Y, Liu L, et al. Cryptotanshinone inhibits cancer cell proliferation by suppressing Mammalian target of rapamycin -mediated cyclin DI expression and Rb phosphorylation [J]. Cancer Prey Res (Phila), 2010, 3 (8): 1015-25.
  • 3Ge Y, Cheng R, Zhou Y, et al. Cryptotanshinone induces cell cycle arrest and apoptosis of muttidrug resistant human chronic myeloid leukemia ceils by inhibiting the activity of eukaryotic initiation factor4E [J]. Mol Cell Biochem, 2012, 368 (1 -2): 17 -25.
  • 4Salvesen GS, Renatus M. Apoptosome : the seven - spoked death machine [J]. Dev Cell, 2002, 2 (3) : 256 -257.
  • 5Lee WY, Liu KW, Yeung JH. Reactive oxygen species - medi- ated kinase activation by dihydrotanshinone in tanshinones - in- duced apoptosis in HepG2 ceils [J]. Cancer Lett, 2009, 285 (1) : 46 -57.
  • 6Kim JH, Jeong SJ, Kwon TR, et al. Cryptotanshinone en- hances TNF - alpha - induced apoptosis in chronic myeloid leu- kemia KBM -5 ceils [J]. Apoptosis, 2011, 16 (7) : 696 - 707.
  • 7Park U, Kim M J, Park O J, et al. Cryptotanshinone sensitizes DU145 prostate cancer cells to Fas (APO1/CD95) -mediated apoptosis through Bcl - 2 and MAPK regulation [ J ]. Cancer Lett, 2010, 298 (1) : 88 -98.
  • 8Shin DS, Kim HN, Shin KD, et al. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells [J]. Cancer Res, 2009, 69 (1) : 193 -202.
  • 9Lee HJ, Jung DB, Sohn E J, et al. Inhibition of Hypoxia Induc- ible Factor Alpha and Astrocyte - Elevated Gene - 1 Mediates Cryptotanshinone Exerted Antitumor Activity in I-Iypoxic PC -3 Cells [ J ]. Evid Based Complement Alternat Med, 2012, 2012 : 390 - 957.
  • 10Chen W, Liu L, Luo Y, et al. Cryptotanshinone activates p38/ JNK and inhibits Erkl/2 leading to easpase - independent cell death in tumor cells [ J]. Cancer Prey Res (Phila), 2012,5 (5) :778 -87.

共引文献200

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部